4Coller BS,Peerschke EI,Scudder LE,et al.A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombosthenic like state in normal platelets and binds to glycoproteins Ⅱb and/or Ⅲa[J].J Clin Invest,1983,72:325.
5Randomised placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-Ⅱb/Ⅲa blockade.The EPISTENT Investigators.Evaluation of platelet Ⅱb/Ⅲa inhibitor for stenting[J].Lancet,1998,352:87.
6The EPIC Investigators.Use of monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa receptor in high-risk coronary angioplasty[J].N Engl J Med,1994,330(14):956.
7Simoons ML.GUSTO Ⅳ-ACS Investigators.Effect of Glycoprotein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO Ⅳ-ACS randomised trial[J].Lancet,2001,357 (9272):1915.
8Scarborough RM,Naughton MA,Teng W,et al.Design of potent and specific integrin antagonists.Peptide antagonists with high specificity for glycoprotein Ⅱb/Ⅲa[J].J Biol Chem,1993,268:1066.
9Jennings L,Tardiff B,Philips D,et al.Comparison of recept or occupancy and platelet aggregation response of epifibatide administered intravenously in patients with unstable angina or non Q wave myocardial infarction[J].J Am Coll Cardiol,1998,31(2A):93A.
10Mahaffey KW,Harrington RA,Simoons ML,et al.Stroke in patients with acute coronary syndromes:incidence and outcomes in the platelet glycoprotein Ⅱb/Ⅲa in unstable angina.Receptor suppression using integrilin therapy (PURSUIT) trial.The PURSUIT Investigators[J].Circulation,1999,99 (18):2371.
